ATE486284T1 - Detektion, überwachung und behandlung von krebs - Google Patents

Detektion, überwachung und behandlung von krebs

Info

Publication number
ATE486284T1
ATE486284T1 AT04719000T AT04719000T ATE486284T1 AT E486284 T1 ATE486284 T1 AT E486284T1 AT 04719000 T AT04719000 T AT 04719000T AT 04719000 T AT04719000 T AT 04719000T AT E486284 T1 ATE486284 T1 AT E486284T1
Authority
AT
Austria
Prior art keywords
detection
treatment
cancer
monitoring
compounds
Prior art date
Application number
AT04719000T
Other languages
English (en)
Inventor
James Bruce
Sotiris Missailidis
Katalin Borbas
Catia Ferreira
Original Assignee
Univ Open
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Open filed Critical Univ Open
Application granted granted Critical
Publication of ATE486284T1 publication Critical patent/ATE486284T1/de

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0491Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/16Aptamers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/351Conjugate
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/351Conjugate
    • C12N2310/3517Marker; Tag
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4725Mucins, e.g. human intestinal mucin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT04719000T 2003-03-10 2004-03-10 Detektion, überwachung und behandlung von krebs ATE486284T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0305422.8A GB0305422D0 (en) 2003-03-10 2003-03-10 Detection, monitoring and treatment of cancer
PCT/GB2004/001028 WO2004081574A2 (en) 2003-03-10 2004-03-10 Detection, monitoring and treatment of cancer

Publications (1)

Publication Number Publication Date
ATE486284T1 true ATE486284T1 (de) 2010-11-15

Family

ID=9954463

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04719000T ATE486284T1 (de) 2003-03-10 2004-03-10 Detektion, überwachung und behandlung von krebs

Country Status (7)

Country Link
US (1) US20070160526A1 (de)
EP (4) EP2209000A3 (de)
AT (1) ATE486284T1 (de)
CA (1) CA2518783A1 (de)
DE (1) DE602004029767D1 (de)
GB (1) GB0305422D0 (de)
WO (1) WO2004081574A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007023766A1 (ja) * 2005-08-23 2007-03-01 National University Corporation Gunma University 含ケイ素置換基を導入した一重項酸素発生剤
WO2007128109A1 (en) * 2006-05-04 2007-11-15 University Health Network Aptamers that recognize the carbohydrate n-acetylgalactosamine (galnac)
GB2437727B (en) * 2006-05-04 2011-04-20 Univ Open Aptamers directed to MUC1
EP2419120A4 (de) * 2009-04-08 2016-01-06 Univ California Menschliches proteingerüst mit gesteuerter serumpharmakokinetik
EP2481800B1 (de) 2009-06-01 2018-02-21 Sungkyunkwan University Foundation For Corporate Collaboration Nukleinsäureaptamer zur speziellen bindung an pankreaskrebszellen oder -gewebe sowie verwendung davon
CN103160513B (zh) * 2011-12-16 2015-07-01 中国医学科学院基础医学研究所 Muc1蛋白核酸适配子、复合体、组合物及其用途
EP2639227A1 (de) * 2012-03-14 2013-09-18 Bracco Imaging S.p.A Neue Klasse von Diazepinderivatchelatbildnern und Komplexe mit paramagnetischen Metallen als MRI-Kontrastmittel
KR102213609B1 (ko) 2012-07-13 2021-02-08 웨이브 라이프 사이언시스 리미티드 키랄 제어
AU2015213483B2 (en) 2014-02-05 2020-07-02 Deakin University Aptamer construct
CN105879027B (zh) * 2014-05-16 2020-03-27 中国科学院苏州纳米技术与纳米仿生研究所 核酸配体修饰的金纳米-石墨烯复合材料及其制备方法和应用
WO2016183207A1 (en) * 2015-05-11 2016-11-17 Northwestern University Cyclen friction modifiers for boundary lubrication
WO2020230047A1 (en) * 2019-05-15 2020-11-19 Affinito Alessadra Aptamers against glioblastoma

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3915958A (en) 1972-05-22 1975-10-28 Icn Pharmaceuticals 6-Substituted purine nucleotides
US3960840A (en) 1972-12-29 1976-06-01 University Of Illinois Foundaton Fluorescent derivatives of adenine-containing compounds
US4038480A (en) 1973-09-17 1977-07-26 Icn Pharmaceuticals, Inc. 6-aminocarbonyl purine 3',5'-cyclic nucleotides
CH614720A5 (de) 1974-10-15 1979-12-14 Asahi Chemical Ind
US3968101A (en) 1974-12-20 1976-07-06 Icn Pharmaceuticals, Inc. 8-Substituted cyclic nucleotides by free radical alkylation and acylation
US4048307A (en) 1974-12-26 1977-09-13 Asahi Kasei Kogyo Kabushiki Kaisha Cyclic adenosine monophosphate 8-substituted derivatives
US4267171A (en) 1979-07-02 1981-05-12 The Regents Of The University Of California C-5 Substituted cytosine nucleosides
US6280932B1 (en) * 1990-06-11 2001-08-28 Gilead Sciences, Inc. High affinity nucleic acid ligands to lectins
US6699843B2 (en) * 1995-06-07 2004-03-02 Gilead Sciences, Inc. Method for treatment of tumors using nucleic acid ligands to PDGF
US6268350B1 (en) * 1997-10-23 2001-07-31 Biocrystal Ltd. Polynucleotides for inhibiting metastasis and tumor cell growth
US6418338B1 (en) * 1998-02-06 2002-07-09 Phylatron Ltd. Method for detecting and surgically removing lymphoid tissue involved in tumor progression
US6224866B1 (en) * 1998-10-07 2001-05-01 Biocrystal Ltd. Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
ES2288040T3 (es) * 1998-12-18 2007-12-16 Bristol-Myers Squibb Pharma Company Medicamentos antagonistas del receptor de la vitronectina.
US6251616B1 (en) * 1999-01-14 2001-06-26 Biocrystal Ltd. Methods and assay kits for detecting altered mononuclear cell phenotype related to a pro-tumor immune response
WO2001052899A1 (en) * 2000-01-21 2001-07-26 Mallinckrodt Inc. Chelating agents and method for their use as tandem metal chelators and hydrophilic spacers for medical diagnosis and therapy
US6673333B1 (en) * 2000-05-04 2004-01-06 Research Corporation Technologies, Inc. Functional MRI agents for cancer imaging
US6376190B1 (en) * 2000-09-22 2002-04-23 Somalogic, Inc. Modified SELEX processes without purified protein
WO2002040060A2 (en) * 2000-10-31 2002-05-23 Bracco International Bv Conjugates of an antioxidants with metal chelating ligands
JP2004529763A (ja) * 2001-04-24 2004-09-30 ティー・エス・コーポレーション 蛋白質を選択的に切断する合成触媒及びこれを用いた蛋白質の選択的切断方法
US20040022727A1 (en) * 2002-06-18 2004-02-05 Martin Stanton Aptamer-toxin molecules and methods for using same

Also Published As

Publication number Publication date
WO2004081574A2 (en) 2004-09-23
DE602004029767D1 (de) 2010-12-09
EP2209000A3 (de) 2010-10-27
GB0305422D0 (en) 2003-04-16
EP2287613A2 (de) 2011-02-23
EP1806585A1 (de) 2007-07-11
EP1601970B1 (de) 2010-10-27
CA2518783A1 (en) 2004-09-23
WO2004081574A3 (en) 2004-12-16
EP1601970A2 (de) 2005-12-07
EP2209000A2 (de) 2010-07-21
US20070160526A1 (en) 2007-07-12

Similar Documents

Publication Publication Date Title
DE60303238D1 (de) Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
DE602004028763D1 (de) Te zur behandlung von virenerkrankungen
ATE527241T1 (de) Pyridiazinonderivate zur behandlung von tumoren
DE602004026891D1 (de) Tlr7-liganden zur behandlung von hepatitis c
ATE453653T1 (de) Platinkomplexe zur behandlung von tumoren
ATE486284T1 (de) Detektion, überwachung und behandlung von krebs
ATE410430T1 (de) 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose
WO2003087831A3 (en) Proteins involved in breast cancer
ATE448232T1 (de) Substituierte heterozyklen
CY1111022T1 (el) Νεοι φαρμακευτικοι συνδυασμοι για τη θεραπεια νοσων των αναπνευστικων οδων
ATE443704T1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
DE602006007481D1 (de) 5-amino-4-hydroxy-7-(imidazo ä1,2-aü pyridin-6-ylmethyl)-8-methylnonamidderivate und verwandte verbindungen als renininhibitoren zur behandlung von bluthochdruck
DE602005013116D1 (de) Pyridin-verbindungen für die behandlung von prostaglandin-vermittelten krankheiten
DE602004003952D1 (de) Substituierte tetrahydrobenzothienopyrimidinamine verbindungen geeignet zur behandlung von hyper-proliferative disorders
ATE425151T1 (de) Verfahren zur racematspaltung von 2,4-diamino-3,6-dihydro-1,3,5-triazinen, die sich zur behandlung von mit dem insulinresistenzsyndrom assoziierten erkrankungen eignen
ATE363431T1 (de) Maschine zur herstellung von filterbeuteln für aufgussprodukte
CY1114757T1 (el) Παραγωγα οξαζινης και η χρηση τους στη θεραπεια νευρολογικων διαταραχων
DE602005012481D1 (de) 2,7-substituierte 5-amino-4-hydroxy-8-(1h-indol-5-yl)-octanamid derivate als renin inhibitoren zur behandlung von bluthochdruck
CY1110043T1 (el) 2-αμινοβενζουλ παραγωγα
DE602006003094D1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit
WO2004085614A3 (en) Nucleic acid molecules that are differentially regulated in a bipolar disorder and uses thereof
ATE424823T1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin- derivate als arzneimittel zur behandlung von unfruchtbarkeit
MXPA01010186A (es) Composiciones y metodos para el tratamiento y diagnostico de cancer de mama.
ITBO20030050A1 (it) Macchina per il trattamento di prodotti farmaceutici.
FR2860234B1 (fr) Nouveaux derives 666 du thioxylose

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties